EAACI Congress 2024

Back

31 May - 03 June 2024 Valencia, Spain

SAT1-2 - Blueprint Medicines – Transforming management of indolent systemic mastocytosis with precision medicine

Friday 31 May, 12:00 PM - 13:00 PM Valencia, Spain

Sevilla Channel Sevilla Sponsored Sessions Access On Demand Section

Objectives

Join our expert faculty as they share their insights on improving diagnosis and disease burden assessment, and discuss the latest updates on precision medicine approaches in indolent systemic mastocytosis*

*La indicación de mastocitosis sistémica indolente (MSI) está aprobada por la EMA pero no está autorizada en España. Avapritinib (AYVAKYT) está comercializado en España para las indicaciones de mastocitosis sistémica avanzada (MS avanzada) y tumores del estroma gastrointestinal (GIST) con mutación PDGFRA D842V.

12:00

Welcome and introductions

Massimo Triggiani (Italy)

12:05

Precision medicine begins with accurate diagnosis: Hallmark symptoms and diagnostic parameters for ISM

Ivan Alvarez Twose (Spain)

12:15

Disease burden in ISM: Using PRO tools to assess the individual patient experience

Frank Siebenhaar (Germany)

12:25

Symptomatic management of ISM: Are we doing enough?

Ivan Alvarez Twose (Spain)